The estimated Net Worth of Colleen Elizabeth De Simone is at least $886 dollars as of 23 October 2017. Colleen Simone owns over 550 units of Syros Pharmaceuticals stock worth over $886 and over the last 7 years Colleen sold SYRS stock worth over $0.
Colleen has made over 1 trades of the Syros Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently Colleen exercised 550 units of SYRS stock worth $1,672 on 23 October 2017.
The largest trade Colleen's ever made was exercising 550 units of Syros Pharmaceuticals stock on 23 October 2017 worth over $1,672. On average, Colleen trades about 550 units every 0 days since 2017. As of 23 October 2017 Colleen still owns at least 550 units of Syros Pharmaceuticals stock.
You can see the complete history of Colleen Simone stock trades at the bottom of the page.
Colleen's mailing address filed with the SEC is 620 Memorial Dr #300, Cambridge, MA 02139, USA.
Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju oraz Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Syros Pharmaceuticals executives and other stock owners filed with the SEC include: